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SUMMARY 
There is a great deal of evidence that in the canine ischaemic preconditioning induced by 
one or more brief episodes of coronary artery occlusion provides marked protection against 
ventricular arrhythmias which result from a more prolonged ischaemic episode. The aim of the 
present study was three fold; (/'), to analyse the time-course of the antiarrhythmic protection 
induced by a single brief 5 ( min) preconditioning occlusion, (/'/), to examine whether the 
antiarrhytmic protection achieved by ischaemic preconditioning can be enhanced or prolonged by 
the coadministration of the angiotensin converting enzyme (ACE) inhibitor enalaprilate or by the 
combined ACE and neutral endopeptidase (NEP) inhibitor Z13752A; both of which are known 
to increase endogenous bradykinin levels, and (///), to investigate the possible antiarrhythmic 
effect of atrial natriuretic peptide (ANP) in our canine model of ischaemia and reperiusion. 
We have demonstrated that one brief (5 min ) period of occlusion of the left anterior 
descending coronary artery (LAD) resulted in marked protection against ventricular arrhythmias, 
induced by prolonged (25 min) occlusion of the same artery. This protection started to fade 15 
min after ischaemic preconditioning and almost completely disappeared if the time interval 
between the preconditioning occlusion and the prolonged occlusion was extended to 60 min. 
Neither enalaprilate nor Z13752A were able to prolong or enhance this antiarrhythmic effect of 
ischaemic preconditioning although both drugs, given alone prior to prolonged ischaemia 
significantly reduced the severity of ventricular arrhythmias during occlusion and increased 
survival of the dogs (50% and 67%, respectively) from the combined ischaemia and reperiusion 
insult. Thus, when these drugs were infused in preconditioning dogs with 15 and 60 min 
reperiusion, the severity of arrhythmias was again increased and survival decreased, particularly 
in preconditioned dogs treated with enalaprilate. We have also demonstrated that ANP markedly 
reduced the incidence and severity of venricular arrhythmias resulted from ischaemia and 
reperiusion. 
We conclude from these results that (/') one single episode of coronary artery occlusion can 
protect the myocardium against severe ventricular arrhythmias and this protection lasts less than 
lh., (/'/) increasing bradykinin levels by drugs in preconditioned dogs does not provide additional 
protection to preconditioning, (/«) ANP protects the myocardium against ischaemia and 
reperfusion-induced ventricular arrhythmias. 
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1. INTRODUCTION 
Interruption of the nutritional blood flow to the heart muscle results in a state of ischaemia. 
The heart muscle cells begin to die approximately 20 min after the onset of ischaemia and 3h later 
the whole ischaemic myocardium virtually becomes infarcted. Myocardial ischaemia is often 
accompanied by serious ventricular tachyarrhythmias, which are still the most common cause of 
sudden cardiac death in the developed countries. This is due, at least in part, to the lack of the 
success of the reperfusion therapy, if the time interval between the onset of the acute ischaemic 
attack and the initiation of treatment increases. In the absence of early reperfusion, more 
myocardium could be saved if the development of ischaemic injury is slowed or delayed. 
1.1. Cardioprotection by brief periods of ischaemia; the phenomenon of ischaemic 
preconditioning 
In 1986, Murry and colleagues (1) showed in anaesthetised dogs that myocardial infarction, 
that resulted from a 40 min coronary artery occlusion and reperfusion of the left circumflex 
coronary artery, was markedly reduced if the same coronary artery had been occluded for four 5 
min periods just prior to the prolonged ischaemia. In these dogs myocardial ATP levels were also 
significantly preserved. This phenomenon was described and termed as "ischaemic 
preconditioning" (1). 
We now know that ischaemic preconditioning not only offers an extremely powerful 
protection against ischaemic damage (2,3), but it also reduces the severity of ischaemia (4-7) and 
reperfusion-induced (6,8,9) ventricular arrhythmias, decreases the postischaemic contractile 
dysfunction (10), enhances the recovery of myocardial function during reperfusion (11-13), 
blunts the loss in vasodilator reserve (14-16) and improves metabolic disturbances that associated 
with myocardial ischaemia (17). These protective effects of preconditioning can occur in all 
species studied so far, such as in dogs (1,5), rats (8,18), rabbits (19,20), pigs (3,21) and also in 
humans (22,23). 
There is now good evidence that preconditioning can be induced by other stimuli than short 
coronary artery occlusions. Thus, rapid cardiac pacing (24), partial occlusion of the coronary 
artery (25), and alteration in myocardial oxygen supply-demand balance (26) can serve as 
preconditioning stimuli. Administration of various substances, such as prostacycline (27), 
adenosine (28), angiotensin converting enzyme (ACE) inhibitor (29), interferon % (30), bacterial 
endotoxin (31), monophosphoryl lipid A (32,33) and nitric oxide donors (34,35) may also 
protect the myocardium. Application of these drugs can be considered as "pharmacological 
preconditioning". 
1.2. The antiarrhythmic effects of ischaemic preconditioning 
There are good reasons for believing that the antiarrhythmic effect of ischaemic 
preconditioning is an even more important manifestation of this adaptive phenomenon than that 
is the reduction in myocardial ischaemic damage (35) since the occurrence of severe ventricular 
6 
arrhythmias and sudden cardiac death, resulting from ventricular iibrilation, are threatening 
consequences of the ischaemia and reperfusion injury. Shiki and Hearse (8) were the first to 
demonstrate the ability of ischaemic preconditioning to protect against reperfusion induced 
arrhythmias in rats. Then, Komori and his colleagues (4) showed in anaesthetized rats, that one 
brief period (3 min) of ischaemia reduced the severity of arrhythmias during a subsequent more 
prolonged (30 min) period of coronary artery occlusion. Using an anaesthetized dog model, 
Vegh and colleagues (5,6) showed that two brief (5 min) periods of occlusion of the left anterior 
desending coronary artery, resulted in marked protection against those ventricular arrhythmias 
which occurred during a 25 min period of occlusion of that same artery. The most striking 
feature of this protection was the absence of ventricular fibrillation in preconditioned dogs during 
occlusion; in contrast to 40% in the controls. Furthermore, all the control dogs died following 
reperfusion whereas 50% of dogs subjected to preconditioning survived the combined ischaemia 
reperfusion insult. The antiarrhythmic effects of ischaemic preconditioning, thus demonstrated in 
rats and dogs, were marked (absence of ventricular fibrillation), real (if the duration of the 
occlusion was extended to 60 min the occurrence of arrhythmias was not shifted to a later time of 
the occlusion), but transient, i.e. the protection was lost if the time interval between the 
preconditioning stimulus and the prolonged occlusion was extended to 30 or 60 min (35-37). 
1.3. The time-dependent characteristics of ischaemic preconditioning 
Among the several unanswered questions, relating to the antiarrhythmic effects of 
preconditioning, one is that which concerns with the number and the duration of the 
preconditioning stimulus required for optimum protection. For example, in rat isolated perfused 
hearts the protection against reperfusion-induced ventricular arrhythmias can be enhanced by 
increasing the number of cycles of the preconditioning occlusion (37). In contrast, a single period 
of preconditioning occlusion for 5 min appears to be sufficient to provide maximal protection 
against myocardial necrosis in dogs and rabbits (38-40) and no further benefit is derived from 
additional cycles. Similarly, Vegh and colleagues showed in anaesthetised dogs that 
preconditioning, induced either by one or two 5 min periods of occlusion, results in almost 
similar protection against ischaemia and reperfusion induced ventricular arrhythmias (41). They 
have also demonstrated that the optimum duration of the preconditioning occlusion against 
arrhythmias in rats is 3 min; 1 min period of preconditioning occlusion was ineffective, whereas 
the 5 min occlusion period resulted in high incidence of ventricular arrhythmias following 
reperfusion (6). Furthermore, Li and colleagues (39) showed in dogs that one 5 min period of 
preconditioning occlusion reduced the incidence of ventricular fibrillation but when the number 
of the preconditioning occlusion had been increased to twelve, the mortality was markedly 
increased during the subsequent prolonged occlusion. There is evidence that repeated, brief 
periods of coronary artery occlusion lead to progressive deterioration of cardiac myocyte 
function especially at the level of the mitochondria (42). In the rabbit, Miura and colleagues (40) 
showed that a single 5 min preconditioning occlusion was more effective to limit infarct size than 
the 2 min period of coronary artery occlusion. However, if this 2 min occulusion was repeated 
twice (2x2 min) the protection was similar to that with a single 5 min preconditioning occlusion. 
Although the protection, resulting from preconditioning is very prounounced, it is transient. The 
power of the protection may depend on the strengh of the ischaemic stimulus. This seems to be 
determined by the number and the duration of the preconditioning occlusion (36,37) and also by 
the time interval that elapse between the preconditioning stimulus and the prolonged ischaemic 
insult (6,36). For example, if the time interval between the preconditioning stimulus and the 
prolonged occlusion is increased to 1 h, the protection is markedly attenuated or even abolished 
(6,43,44). However, the protection reappears 24 h later and then it may last for at least 72 h (45-
47). This second phase of the protection is termed as delayed, or "second window of protection" 
(48). 
1.4. The possible mechanisms of ischaemic preconditioning; involvement of endogenous 
myocardial protective substances 
Although the precise mechanism of ischaemic preconditioning is still uncertain, most of the 
investigators accept the hypothesis that endogenous myocardial substances, released either from 
ischaemic cardiac myocytes or endothelial cells or both, are involved (49-51). These mediators, 
which are released during the early phase of myocardial ischaemia, might be either protective 
(adenosine, nitric oxide, prostanoids, bradykinin) or potentially detrimental (endothelin, 
noradrenaline, potassium, etc; 50). It is also likely that more than one protective mediator is 
released during ischaemia to compensate the harmful consequences of the ischaemic injury. 
These endogenous mediators, acting at different receptors, might induce protection in different 
ways or, perhaps, there is a final common pathway. The role of adenosine, as originally described 
by Downey and colleagues (19), with the subsequent activation of protein kinase C (52), in 
mediating the limitation of infarct size associated with ischaemic preconditioning, is well 
described in most species. However, it seems likely that adenosine plays no substantial role in the 
antiarrhythmic effect of ischaemic preconditioning either in rats (53,54) or dogs (55), despite the 
fact that in these species adenosine is an endogenous antiarrhythmic substance (56). The first 
evidence, that other endogenous protective substances, such as bradykinin, nitric oxide and 
prostanoids, are also involved in the cardioproptective effects of ischaemic preconditioning, 
comes from studies performed in anaesthetised dogs (35,57,58). According to this hypothesis, as 
illustrated in figure 1, during the early stages of ischaemia (i.e. preconditioning), bradykinin is 
released from endothelial cells. This activates endothelial bradykinin B2 receptors and induces the 
formation and the release of nitric oxide (NO) and prostacyclin from endothelial cells. Nitric 
oxide then diffuses to cardiac myocytes, stimulates soluble guanylate cyclase and elevates cyclic 
GMP levels. This would reduce myocardial contractility and energy demand perhaps by 
stimulating the cGMP-dependent phosphodiesterase enzyme. Cyclic GMP could also inhibit the 
voltage-dependent L-type calcium channels (59) and reduce the influx of calcium which is a key 
player in the generation of arrhythmias and also in myocardial cell death. 
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Figure 1. Possible mechanisms involved in the antiarrhythmic effects of preconditioning 
(adapted, by permission, from ref 35). 
1.4.1. The role of bradykinin in the antiarrhythmic effects of ischaemic preconditioning 
The first evidence that bradykinin might be involved in the cardioprotective effects of 
preconditioning comes first from studies of Vegh and colleagues (60,61). They showed in 
anaesthetised dogs that local administration of bradykinin markedly reduced the severity of 
ventricular arrhythmias resulted from a 25 min occlusion of the left anterior descending coronary 
artery (60). Furthermore, the protective effect of preconditioning against arrhythmias was 
abolished by icatibant, a selective antagonist of bradykinin at bradykinin B2 receptors (61). They 
have also demonstrated that the antiarrhythmic effect of bradykinin is largely mediated by NO, 
since the protection was markedly attenuated in the presence of L-NAME (62). Similarly, 
Hecker and colleagues reported that activation of bradykinin B2 receptors is responsible for the 
release of prostacycline and the generation of nitric oxide by bradykinin (63). 
There is evidence that bradykinin levels can be elevated by other means than ischaemic 
preconditioning. It is well documented that ACE plays an important role role in bradykinin 
metabolism and that inhibition of ACE elevates bradykinin levels (64-66). The cardioprotective 
effects of ACE inhibition in myocardial ischaemia are well documented both in expenmental 
animals (67,68) and humans (69,70) and there is a clear role for bradykinin in mediating these 
protective effects (64,67,71-73). The other enzyme which is also involved in bradykinin 
metabolism is the neutral endopeptidase (NEP) which is a membrane bound metallopeptidase 
present in endothelial cells (74) and in cardiomyocytes (75). NEP has a high affinity for a variety 
of vasoactive peptides including substance P, bradykinin, atrial natriuretic peptide (ANP) and 
endothelin (74). In the heart this is a particularly important enzyme responsible for kinin 
degradation (75-77). If we accept the hypothesis that bradykinin is an important mediator of 
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ischaemic preconditioning and that drugs which inhibit both ACE and NEP enzymes act by 
elevating bradykinin levels, then we might expect that these drugs can mimic the protective 
effects of preconditioning and they would be important in the therapy of ischaemic heart disease. 
Such a combined ACE/NEP inhibitor is the Z13752A (N-[(2S)-3-mercapto-2-
phenylmethylpropionyl]-4-(2-thiazolyl)-L-phenylalanine) compound. Z13752A is a newly 
developed ACE/NEP inhibitor with an IC50 of 3.2 nM on ACE and of 1.8 on NEP (78). 
Z13752A has been found to potently inhibit plasma and tissue ACE, as well as tissue NEP activity 
in various in vitro and in vivo experiments. Z13752A resulted in a long lasting antihypertensive 
effect in both SHR and DOCA-salt hypertensive rats after intravenous or oral administration 
(79,80). 
1.4.2. The role of nitric oxide in ischaemic preconditioning 
Vegh and colleagues porposed for the first time that nitric oxide is involved in the 
antiarrhythmic effects of ischaemic preconditioning. In anaesthetised dogs inhibition of the L-
arginine-nitric oxide pathway by L-NAME (N°-nitro-arginine methyl ester) markedly attenuated 
the antiarrhythmic effects of preconditioning (81). Similarly, the local, intracoronary infusion of 
methylene blue (an inhibitior of both L-arginine-NO synthesis and guanylyl cyclase enzyme) 
completely abolished the protective effect of preconditioning against arrhythmias (82). Thus, it 
was concluded that NO, acting through the guanylyl-cyclase-cGMP system, is one of the main 
mediators of the antiarrhythmic effects of classical preconditioning (81). 
The proposal, that elevation of cGMP in the myocardium might reduce the susceptibility to 
ventricular arrhythmias, raised first by Opie (83). This was confirmed by studies of Billman (84), 
using a canine model with healed myocardial infarction. He showed that both carbacol and 8-
bromo-cyclic GMP reduced the incidence of ventricular fibrillation, induced by a brief coronary 
artery occlusion and exercise. Elevation of cGMP can influence arrhythmogenesis in different 
ways (Figure 1). These might include depression of myocardial contractility by nitric oxide (85), 
inhibition of calcium influx through the L-type calcium channels (86) and stimulation of cGMP 
dependent phosphodiesterase and subsequent reduction in myocardial cAMP levels. 
1.4.3. The cardioprotective effects of atrial natriuretic peptide 
ANP is another endogenous myocardial substance which elevates myocardial cGMP. This 
peptide is secreted into the circulation mainly from the atrium (87) in response to a variety of 
stimuli, such as atrial stretch (88), acut hypoxia (89), and cardiac pacing (90). ANP has a wide 
range of potent biological effects, including coronary vasodilation (91,92), natriuresis and 
inhibition of the renin-angiotensin-aldosterone system (93). Marmuo and colleagues reported that 
ANP aguments induction of iNOS in the rat vascular smooth muscle cells (94). Similarly, 
Yamamoto and colleagues showed that ANP potentiates the cytokine-stimulated NO synthesis in 
cardiac myocytes and this is mediated partially via activation of a cGMP-dependent protein 
kinase (95). In a canine model, Takata and colleagues (96) found that administration of ANP 
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elevates cGMP and prevents reperfusion arrhythmias. However, there is no information whether 
ANP reduces ischaemia-induced ventricular arrhythmias. 
1.5. Aim of the study 
1. To analyse the time-course of the antiarrhythmic protection induced by a single brief (5 min) 
preconditioning occlusion in anaesthetised dogs. 
2. To examine the effect of the ACE inhibitor enalaprilate and the combined ACE/NEP inhibitor 
Z13752A against ischaemia and reperfusion-induced ventricular arrhythmias in anaesthetised 
dogs. 
3. To explore whether protection, resulted from ischaemic preconditioning, can be enhanced or 
prolonged by elevating bradykinin levels. For this purpose enalaprilate and Z13752A were 
administrated in preconditioned dogs. Both drugs supposed to increase bradykinin levels. 
4. To examine whether ANP, given intravenously in anaesthetised dogs, protects the myocardium 
against ischaemia and reperfusion-induced ventricular arrhythmias. 
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2. METHODS 
2.1. Experimental animals 
Adult mongrel dogs of either sex, weighing in excess of 17 kg and allowed to access to food 
and water ad libitum a day before until starting the experiments, were used. All animals received 
humane treatment according to the Guide for the Care and Use of Laboratory Animals published 
by the US National Institutes of Health (NIH publication number NO 85-23, 1985) and local 
institutional policy. 
2.2. Surgical interventions 
Dogs were anaesthetised intravenously with a mixture of chloralose and urethane (60 and 200 
mg kg*1, respectively) and ventilated with room air using a Harvard ventilator at a rate of 15 
strokes min'1. The stroke volume was adjusted to maintain pH and blood gases within normal 
limits: pH 7.40 ± 0.04; Pa02 85 ± 1.3 mm Hg, PaCo2 30 ± 1.1 mmHg. Body temperature was 
monitored from the oesophagus and maintained at 37 ± 0.6 °C by means of a heating pad. 
Thoracotomy was performed at the fifth intercostal space and the heart was suspended in a 
pericardial cradle. The anterior branch of the left coronary artery (LAD) was dissected free about 
2 cm from its origin, just above the first marginal branch, and a silk thread was loosely placed 
around it (Figure 2). Myocardial ischaemia was induced by passing the thread through a small 
plastic tube and then pulling the suture while pressing the tube against the surface of the 
myocardium. Reperfiision was initiated by releasing the ligature and removing the plastic tube. In 
some experiments, proximal to the occlusion site, a Doppler flow probe was placed around the 
coronary artery by which changes in flow velocity (cm s"1) were evaluated. The circumflex 
branch (LCX) of the left coronary artery was also prepared. An electromagnetic flow probe was 
placed around this coronary artery, attached to a Statham SP 2202 flowmeter. 
Polyvinyl catheters were inserted into the right femoral artery for monitoring arterial blood 
pressure (systolic: SABP and diastolic DABP), into the left ventricle via the left carotid artery to 
measure the left ventricular systolic (LVSP) and end-diastolic (LVEDP) pressures and dP/dim» 
Catheters introduced into the right femoral vein were used for the administration of anaesthetic 
and drugs. All these parameters were measured by means of a Statham P23XL pressure 
transducer and recorder on a Medicor R-81 recorder (Figure 2). 
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Figure 2. The experimental model in anaesthetised dogs for the measurements of the 
haemodynamic parameters, epicardial ST-segment changes, the degree of inhomogeneity of 
electrical activation and for the assessment of ventricular arrhythmias. 
2.3. Assessment of the severity of myocardial ischaemia 
The severity of myocardial ischaemia following coronary occlusion was assessed by 
evaluating changes in epicardial ST-segment (mV) and in the degree of inhomogeneity of 
electrical activation (msec). These were measured by means of a small rubber pad (composite 
electrode), containing 32 measuring points, ended in a bipolar lead for the measurement of 
inhomogeneity and four unipolar electrodes by which changes in epicardial ST-segment were 
evaluated. The composite electrode was sutured on the epicardial surface of the myocardium 
within the ischaemic zone (Figure 2). Inhomogeneity was determined from the summarised 
recording of R-waves, collected from these 32 epicardial measuring points. In the adequately 
perfused and oxygenated myocardium all sites are activated virtually simultaneously, resulting in a 
large single spike. However, following occlusion, widening and fractionation of the summarized 
R-waves occurs, indicating that adjacent fibres are not simultaneously activated because of 
inhomogeneity of conduction (97). 
2.4. Evaluation of ventricular arrhythmias 
Ventricular arrhythmias, occurring following ischaemia and reperfusion, were analysed 
according to the "Lambeth Conventions" (98), except that no distinction was made between 
couplets and salvos, which were included as single ventricular ectopic (premature) beats (VPBs), 
and that we defined ventricular tachycardia (VT) as a run of four or more ectopic beats at a rate 
faster than the resting sinus rate. We also evaluated the number of episodes of ventricular 
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tachycardia (VT) which occurred in each dog, as well as the incidences of VT and ventricular 
fibrillation (VF) during occlusion. The only arrhythmia that we evaluated during reperfiision was 
VF. Survival indicates those dogs that were predominantly in sinus rhythm 10 min after 
reperfusion. 
2.5. The measurement of the area at risk 
Since the size of the occluded area can modify the severity of ventricular arrhythmias, at the 
end of the experiments the 'area at risk' was assessed by infusing patent blue V dye into the 
occluded artery at a pressure equivalent to that of mean arterial pressure. The risk area was then 
measured and expressed as the precentage of the left ventricular wall including the septum. 
Z13752A was a kind gift from Zambon, Milan, Italy. Enalaprilate, ANP, oc-Chloralose and 
Urethane were purchased from Sigma, Grenoble, France. Icatibant (Hoe-140) was provided by 
Hoechst AG., Germany. 
2.7. Statistical evaluation 
All data were expressed as means ± s.e.mean and the differences between means were 
compared by analysis of variance (ANOVA for repeated measures) or the Student's /-test as 
appropriate. A one-way ANOVA was undertaken to determine whether or not there were 
significant haemodynamic differences between the groups. VPBs were compared by using the 
Mann-Whitney Rank sum test, and the incidences of arrhythmias were compared using the Fisher 
Exact test. Diferences between groups were considered significant when P< 0.05. 
2.8. Experimental protocols 
2.8.1. Experimental protocol to examine the time-course of preconditioning induced by a 
single brief (5 min) preconditioning occlusion 
In this study 5 groups of dogs were used. In the control group (group 1; n = 16) dogs were 
infused with saline for 60 min and then subjected to a 25 min occlusion of the LAD. The 
coronary artery was then opened, to allow for rapid reperfusion. Four groups of dogs were 
subjected to preconditioning by occluding the LAD for 5 min. At various time afterwards (i.e. 5 
min in group2, n = 9; 15 min in group3, n = 8; 30 min in group4, n = 8 and 60 min in group5, n 
= 12) these dogs were subjected to prolonged occlusion (Figure 3). 
2.6. Drugs 
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Figure 3. Experimental protocol for evaluating the time-course of classical preconditioning 
2.8.2. Experimental protocol for evaluating the antiarrhythmic effects of enalaprilate 
and Z13752A 
In this study we examined the effects of enalaprilate and Z13752A on responses of acute 
coronary artery occlusion and reperfusion in anaesthetized dogs (Figure 4). 
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Figure 4. Experimental protocol to examine the effects of enalaprilate, Z13752A and Z13752A 
in the presence of icatibant. 
Ten dogs were infused with enalaprilate, in a dose of 5 pg kg"1 min'1 and 9 dogs with 
Z13752A, in a dose of 128 pg kg'1 min"1 intravenously over a period of 60 min. At the end of the 
infusion the LAD was occluded for 25 min followed by reperfusion. In a third group of 11 dogs, 
icatibant, an antagonist of bradykinin at B2 receptors, was given intravenously in a dose of 0.3 mg 
kg"1, starting the infusion 10 min prior to coronary artery occlusion. A fourth group of 12 dogs 
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was also infused with Z13752A, as described above, but 50 min later these dogs were given 
icatibant. The responses were compared with those of 16 control dogs which were infused with a 
similar volume of the vehicle for 60 min and then subjected to coronary artery occlusion followed 
by reperfusion (Figure 4). 
2.8.3. Experimental protocol to examine whether protection induced by 
preconditioning can be enhanced or prolonged by enalaprilate or Z13752A 
In this part of the study we examined whether the antiarrhythmic effect of preconditioning 
can be enhanced or prolonged by the administration of enalaprilate and Z13752A, giving these 
drugs in preconditioned dogs at a time when the protection resulted from preconditioning was 
still present or has already faded. For this purpose preconditioned dogs with reperfusion intervals 
of 15 and 60 min were used (see the protocol in section 2.8.1.). In two groups of dogs, in which 
the reperfusion interval between the preconditioning occlusion and the prolonged occlusion was 
15 min, either enalaprilate (n = 6) or Z13752A (n = 6) was infused in doses as described above 
(see section 2.8.2.), commencing the infusions 60 min prior to prolonged ischaemia (Figure 5a). 
Other groups of preconditioning dogs, with a reperfusion interval of 60 min, were also infused 
with enalaprilate (n = 13) and with Z13752A (n = 12), starting the infusions immediately after the 
preconditioning occlusion (Figure 5b). The results obtained from these experiments were 
compared to those groups in which dogs were simply subjected to preconditioning with 15 min 
and 60 min reperfusion intervals (described in section 2.8.1) and to dogs which were treated with 
either enalaprilate or Z13752A (described in section 2.8.2.), as well as to the controls. 
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Figure 5. Experimental protocol to explore whether protection induced by preconditioning can 
be enhanced or prolonged by enalaprilate or Z13752A. 
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2.8.4. Experimental protocol to examine the antiarrhythmic effect of atrial natriuretic 
In these studies 2 groups of dogs, were used. In eleven dogs human synthetic ANP was given 
intravenously in a bolus injection of 10 p.g kg"1 followed by infusion of 0.1 p.g kg'1 min"1 over a 
period of 40 min, commencing 30 min prior to, and 10 min during the 25 min occlusion of the 
LAD. The responses were compared with those of 14 control dogs which were given a similar 
volume of saline and then subjected to coronary artery occlusion for 25 min. The artery was then 
re-opened rapidly to allow reperfusion (Figure 6). 
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Figure 6. Experimental protocol to evaluate the effects of ANP. 
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3. RESULTS 
3.1. Evaluation of the duration of the antiarrhythmic effects of preconditioning induced by 
a single 5 min occlusion of the LAD in anaesthetised dogs 
3.1.1. Haemodynamic changes following coronary artery occlusion in control and in 
preconditioned dogs 
These are summarised in Table 1. In all groups, occlusion of the LAD resulted in similar 
reduction in arterial blood pressure. However, reductions in LVSP, positive and negative 
LVdP/dW were significantly less pronounced and the increase in LVEDP was less marked in 
the preconditioned dogs with 5 min, 15 min, 30 min reperfiision intervals than in the controls. 
These haemodynamic changes in preconditioned dogs with 60 min reperfiision were, however, 
similar to the controls. 
Occlusion of the LAD resulted in marked and prolonged increase in blood flow of the LCX 
coronary artery as a result of the significant reduction in coronary resistance. This compensatory 
flow increase was somewhat more pronounced in the preconditioning dogs than in the controls 
(Table 1). 
3.1.2. The severity of myocardial ischaemia during a 25 min occlusion of the LAD in 
control and in preconditioned dogs 
In our experiments the severity of myocardial ischaemia was assessed by two parameters; 
changes in the epicardial ST-segment and the degree of inhomogeity of electrical activation, both 
measured within the ischaemic myocardium. In control dogs, coronary artery occlusion resulted 
in a significant elevation in the epicardial ST-segment (Figure 7a) and a marked increase in the 
degree of inhomogeneity of electrical activation (Figure 7b). One 5 min preconditioning 
occlusion markedly reduced these indices of ischaemia severity. Thus, compared to the controls, 
the epicardial ST-segment elevation was significantly less pronounced in all groups of the 
preconditioned dogs (Figure 7a). Similarly, the degree of inhomogeniety of electrical activation 
was less marked in dogs subjected to preconditioning than in the controls, except that group in 
which the time interval between the preconditioning occlusion and the prolonged ischaemia was 
extended to 60 min (Figure7b). 
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Table 1. Haemodynamic changes during a 25 min occlusion of the LAD in control and in preconditioned dogs. 
Control PC 5 min R PC 15 min R PC 30 min R PC 60 min R 
(n = 16) (n = 8) (n = 9) (n = 11) (n = 12) 
Initial value max. change Initial value max. change Initial value max. change Initial value max. change Initial value max. change 
Arterial blood pressure 
systolic (mmHg) 125 ± 5 -14 ± 2 * 113 ± 4 -12 ± 3 * 101 ± 2 -11 ± 3* 116 ± 6 -13 ± 3 * 124 ± 5 -14 ± 3* 
diastolic (mmHg) 90 ± 4 -13 ± 1* 73 ± 3 -8 ± 1* 65 ± 3 -8 ± 2 * 80 ± 3 -7 ± 2*# 87 ± 3 -10 ± 1* 
mean (mmHg) 102 ± 4 -13 ± 3 * 84 ± 3 -10 ±1.5* 77 ± 2 -9 ± 2 * 93 ± 4 -9±2* 99 ± 4 -14 ± 5 * 
LVSP (mmHg) 128 ± 7 -16 ± 3 * 120 ± 4 -11± 2*# -106 ± 2 -7 ± 4*# 122 ± 5 -10 ± 2*# 117 ± 5 -14 ± 2 * 
LVEDP (mmHg) 6.0 ± 0.3 12.7 ±0.6* 5 ±0.3 9.1 ± 1.2*# 6.3 ±0.6 4.8 ± 1.5*# 6.0 ±0 .4 10.0 ± 2.1*# 5.2 ±0.5 12.1 ±0.8* 
LVdP/dtmax: 
(+ve: mmHg s"1) 2622 ±216 -644 ± 99* 3136 ±233 -427 ± 200*# 2784 ± 177 -267 ±123*# 2834 ± 269 -441± 82*# 3466 ± 342 -311 ±95* 
(-ve: mmHg s"') 2914 ±242 -641 ±116* 2805 ±172 -117 ± 51# 2594 ±174 -194±84# 2784±171 -226 ± 70# 2844 ±212 -433 ± 76* 
Heart rate (beats min"1) 155 ± 4 1 ± 1 134 ± 4 3 ± 1 127 ± 5 2 ± 1 141 ± 6 9 ± 2 * 148 ± 6 7 ± 2 * 
Coronary (LCX) diastolic 
blood flow (ml min'1) 
82 ± 8 14 ± 3 * 164 ± 11 27 ± 4*# 156 ±31 31 ± 7*# 113 ± 21 35 ± 7*# 156 ± 12 44 ± 5*# 
Coronary (LCX) diastolic 1.13 ±0.12 -0.23 ±0.05 0.44 ±0.02 -0.10 ±0.01* 
resistance (mmHg ml"1 
min'1) 
*P < 0.05 vs initial (valuepre-occlusion); U P < 0.05 vs control. 
-0.51 ±0.1 -0.21 ±0.04* 0.88 ±0.15 -0.21 ±0.05* 0.56 ±0.03 -0.81 ±0.65* 
Figure 7. Changes in epicardial ST-segment elevation (a) and in the degree of inhomogeneity 
of electrical activation ( b) during a 25 min occlusion of the LAD in control dogs (open 
circles) and in dogs preconditioned 5 min (open squares), 15 min (filled circles), 30 min 
(open rhombs) and 60 min (filled squares) previously. *P < 0.05 vs controls. 
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3.1.3. Time-course of the antiarrhythmic protection resulted from a single 5 min 
occlusion of the LAD 
Figure 8 illustrates the severity of ventricular arrhythmias that occur during a 25 min 
occlusion and reperfusion of the LAD in control dogs and in dogs subjected to preconditioning 
at various time intervals previously. Compared to the controls, preconditioning significantly 
reduced the number of VPBs (353 ± 79 to 83 ± 37, 72 ± 27 and 32 ± 9), the number of 
episodes of VT (10.7 ±3 .3 to 1.6 ± 0.7, 0.3 ± 0.2 and 0.4 ± 0.2) and the incidence of VT 
(100% to 62%, 25% and 37%) during coronary artery occlusion, if the time interval between 
the preconditioning occlusion and the prolonged occlusion was 5, 15 and 30 min, respectively. 
None of these preconditioned dogs fibrillated during occlusion, in contrast to 44% in the 
controls (Figure 8). Survival from the combined ischaemia-reperfusion insult, thus significantly 
increased in the preconditioned dogs (63%, 38% and 38% cp controls 0%). This 
antiarrhythmic protection was almost completely abolished if the time interval between the 
preconditioning occlusion and the prolonged occlusion had been extended to 60 min (VPBs: 
273 ± 87, VT episodes: 8 ± 4.1, VT incidence: 58%, occlusion VF incidence: 17%, 
reperfusion VF incidence: 66%, survival: 17%; Figure 8). 
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Figure 8. The incidence and the severity of ventricular arrhythmias resulting from coronary 
artery occlusion and subsequent reperfusion in anaesthetised control dogs and in dogs 
preconditioned 5 min, 15 min, 30 min and 60 min previously. *P < 0.05 vs controls. 
3.2. The cardioprotective effects of enaiaprilate and Z13752A in anaesthetised dogs. The 
role of bradykinin 
3.2.1. The haemodynamic effects of enaiaprilate, Z13752A, icatibant and Z13752A in 
the presence of icatibant 
These data are summarised in Table 2. Intravenous infusions of Z13752A and enaiaprilate 
resulted in significant reductions in arterial blood pressure, left ventricular systolic pressure and 
negative LVdP/dtmax without substantialy affecting LVEDP. In addition, enaiaprilate also 
significantly reduced heart rate and positive LVdP/dtmax. Both drugs caused marked increase in 
coronary blood flow through the circumflex branch of the left coronary artery as a result of a 
decrease in coronary vascular resistance (Table 2). 
Icatibant given alone resulted in no significant haemodynamic changes. There was only a 
moderate increase in arterial blood pressure and a slight decrease in positive dP/dtmax. However, 
this dose of icatibant completely abolished the haemodynamic effects ofZl3752A (Table 2). 
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Table 2. Haemodynamic changes following intravenous infusions of enalaprilate, Z13752A 
icatibant and Z13752A in the presence of icatibant. 
Enalaprilate Z13752A Icatibant Z13752A + Icatibant 
(n = 10) (n = 9) (n = U) (n = 12) 
Initial value max. change Initial value max. change Initial value max. change Initial value max. change 
Arterial blood pressure 
systolic (mmHg) 124 ±3 -29 ±3* 129 ±16 -12 ± 4*# 118±4 3 ±0.8 125 ±3 7 ±3* 
diastolic (mmHg) 79 ±2 -27 ±4* 80 ±9 -9 ± 3*# 84 ±3 3 ±0.9 86 ±3 5 ±2* 
mean (mmHg) 94 ±2 -28 ± 3* 97 ± 11 -11 ±3*# 95 ±3 4± 1* 98 ±3 5± 1* 
LVSP (mmHg) 116±3 -25 ± 4» 134 ± 10 -11 ± 4*# 111 ± 4 2 ±0.7 110 ±4 3 ±3 
LVEDP (mmHg) 5.0 ±0.4 0 ± 0 5.6 ±1.0 0.3 ± 0.7 5 ±0.2 0.7 ±0.5 5.0 ±0.6 0.3 ±0.2 
LVdP/dW 
(+ve: mmHg s"1) 3778 ±144 -771± 113* 3666 ±305 -133 ± 184# 3137 ±169 -274 ± 123 4061 ±206 -336 ±130* 
(-ve: mmHg s'1) 3067 ±137 -599±129* 3242 ±461 -363 ± 167* 2747 ±86 -402 ±207 2807 ±226 -80 ± 150 
Heart rate (beats min"1) 150 ± 7 -6± 1* 142 ±7 -4±2 153 ± 7 -4± 1* 161 ±6 -5 ±2* 
Coronary (LCX) diastolic 
blood flow (ml min'1) 
111 ± 5 11 ±3* 113 ±13 14 ±5* 83 ±5 -9 ±3 102 ±7 -3 ±5 
Coronary (LCX) diastolic 
resistance (mmHg ml"1 min'1) 
0.82 ±0.10 -0.38 ±0.11* 0.81 ±0.13 -0.63 ±0.11* 1.04 ±0.08 0.15 ±0.05 0.87 ±0.05 0.09 ±0.06 
*P < 0.05 vs initial (value pre-drug), #P < 0.05 vs enalaprilate. 
3.2.2. Haemodynamic changes induced by coronary artery occlusion in control dogs, 
and in dogs given enalaprilate, icatibant, Z13752A and Z13752A in the presence of 
icatibant 
These results are summarised in Table 3. Occlusion of the LAD resulted in almost similar 
decreases in arterial blood pressure, LVSP and LVdP/dWin all dogs. However, the occlusion-
induced increase in LVEDP was significantly less pronounced in dogs given enalaprilate or 
Z13752A than in the control dogs or in dogs given icatibant either alone or in the presence of 
Z13752A (Table 3). 
In all groups, occlusion of the LAD led to an immediate increase in blood flow of the other 
major (circumflex) branch of the left coronary artery. This 'compensatory' flow increase was 
somewhat more pronounced in dogs treated with icatibant either alone or in the presence of 
Z13752A (Table 3). 
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Table 3. Heamodynamic changes following occlusion of the LAD in dogs pretreated with saline, enalaprilate, Z13752A, icatibant and with 
Z13752A in the presence of icatibant. 
Control Enalaprilate Z13752A Icatibant Z13752 + Icatibant 
(n = 16) (n = = 10) (n = 9) (n = = 11) (n = = 12) 
Initial value max. change Initial value max. change Initial value max. change Initial value max. change Initial value max. change 
Arterial blood pressure 
systolic (mmHg) 125 ± 5 -14 ± 2 * 95 ± 3 -12 ± 3 * 117 ± 3 -13 ± 3 * 114 ± 4 -20 ± 5* 131 ± 4 -15 ± 2 * 
diastolic (mmHg) 90 ± 4 -13 ± 1 * 52 ± 3 -5 ± 2 *# 71 ± 3 -7 ± 2*# 81 ± 4 -19 ± 4 * 92 ± 3 -13 ± 2 * 
mean (mmHg) 102 ± 4 -13 ± 3 * 66 ± 3 -7 ± 2 * 86 ± 3 -9 ± 2 * 92 ± 4 -19 ± 1* 105 ± 3 -14 ± 2 * 
LVSP (mmHg) 128 ± 7 -16 ± 3 * 91 ± 4 -8 ± 2*# 123 ± 5 -13 ± 4 * 108 ± 4 -20 ± 4* 117 ± 3 -15 ± 2 * 
LVEDP (mmHg) 6.0 ± 0.3 12.7 ± 0.6* 4.8 ±0.5 8.6 ± 1*# 5.3 ±0.3 8.3 ± 1.5*# 4.0 ± 0.4 16.0 ± 1.2*# 5.3 ±0.7 14.1 ±0.9* 
LVdP/dW: 
(+ve: mmHg s"1) 2622 ± 216 -644± 99* 3149 ±248 -729 ± 87* 3666 ± 252 -635 ± 264* 3315 ±274 -624 ±139* 3275 ±213 -1134 ± 160* 
(-ve: mmHgs"1) 2914 ±242 -641±116* 2620 ± 136 -551±104* 2879 ± 252 -165 ± 131# 2748 ± 278 -551±106* 3126 ±320 -487 ± 133* 
Heart rate (beats min'1) 155 ± 4 1± 1 144 ± 7 1 ± 3 138 ± 8 3 ± 2 149 ± 7 5 ± 2 157 ± 6 10 ± 3 * 
Coronary (LCX) diastolic 
blood flow (ml min"1) 
82 ± 8 14 ± 3 * 101 ± 8 21 ± 4 * 123 ± 18 21 ± 3 * 82 ± 4 35 ± 8*# 99 ± 9 40 ± 4*# 
Coronary (LCX) diastolic 1.13 ± 0.12 -0.23 ± 0.05* 0.54 ± 0.04 -0.15 ±0.09* 0.70 ±0.12 -0.21 ±0.01* 1.04 ±0.03 -0.30 ± 0.66* 0.98 ± 0.08 -0.41 ±0.06* 
resistance (mmHg ml'1 min'1) 
*P < 0.05 v.v initial (value pre-occlusion); UP < 0.05 vs control. 
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3.2.3. Angiotensin responses before and after enalaprilate and Z13752A treatment 
In order to evaluate the inhibitory effects of enalaprilate and Z13752A on ACE, in a 
separate group of dogs the responses to intravenous bolus injections of angiotensin I (AG I) 
and angiotensin II (AG II), in doses of 5, 10, 15 and 20 ng kg"1 were examined prior to and at 
the end of the 60 min infusion period of enalaprilate (n = 9; Figure 9b) and Z13752A (n = 11; 
Figure 9c). All these responses were compared to those obtained from control dogs (n = 6; 
Figure 9a) in which enalaprilate and Z13752A were replaced by the vehicle. The AG I 
responses were significantly reduced after any of these two drugs (Figure 9b and 9c). 
Interestingly, the AG II responses were significantly potentiated at all dose levels after 
administration of Z13752A (Figure 9c). 
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Figure 9. Changes in arterial blood pressure induced by bolus injections of AGI and AGII 
given before or after the administration of the vehicle (a), enalaprilate (5 pg kg min', b) 
and Z13752A (128 pg kg min', c). *P < 0.05 vs before drug treatment; UP < 0.05 vs 
control. §P < 0.05 vs enalaprilate 
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3.2.4. Bradykinin responses before and after Z13752A administration 
In these experiments we tested whether inhibition of ACE and NEP enzymes with 
Z13752A would result in enhanced responses to bradykinin. Therefore, in a separate group of 
dogs intravenous bolus injections of bradykinin were given in doses of 0.1, 0.25, 0.5 and 1 pg 
kg'1 prior to and after the administration of Z13752A (n = 4) and changes in arterial blood 
pressure were compared to the pre-drug values and to the vehicle treated dogs (n = 4, Figure 
10a). Bradykinin responses were significantly potentiated at all dose levels after the 
administration of Z13752A (Figure 10b). 
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Figure JO. Changes in arterial blood pressure induced by bolus injections of bradykinin given 
before and after the administration of the vehicle (a) and of Z13752A (128 pg kg min', b). 
*P < 0.05 vs before drug administration; #P < 0.05 vs controls. 
3.2.5. The severity of myocardial ischaemia following coronary artery occlusion in 
control dogs and in dogs treated with enalaprilate, Z13752A, icatibant and with the 
combination of Z13752A and icatibant 
The epicardial ST-segment and the degree of inhomogeneity of electrical activation 
(Figures 1 la and lib) were rapidly increased within the first 5 min of the onset of coronary 
artery occlusion. These changes were significantly less marked in dogs given either enalaprilate 
or Z13752A (Figures 11a and lib). Icatibant reversed the protective effects of Z13752A on 
these indices of ischaemia severity (Figuresl la and 1 lb). 
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Figure 11. Changes in epicardial ST-segment (a) and in the degree of inhomogenity of 
electrical activation (b) during a 25 min occlusion of the LAD in anaesthetised dogs, given 
saline (open circles), enalaprilate (filled squares), Z13752A (filled circles), icatibant (open 
triangles) and Z13752A in the presence of icatibant (open squares). *P < 0.05 vs controls. 
3.2.6. The effects of enalaprilate, Z13752A, icatibant and Z13752A together with 
icatibant on ventricular arrhythmias following coronary artery occlusion and 
reperfusion 
This is illustrated in Figure 12. Both enalaprilate and Z13752A markedly reduced the 
incidence and the severity of ventricular arrhythmias, resulted from a 25 min occlusion of the 
LAD. Thus, compared to the controls, in dogs given enalaprilate and Z13752A, the number of 
VPBs (353 ± 7 9 to 103 ±42 and 91 ±40), the number of episodes o f V T (10.7 ± 3.3 to 1.8 ± 
1.2 and 0.22 ± 0.15), the incidences of VT (100% to 40% and 22%) and VF (44% to 30% and 
0%) during occlusion were markedly reduced and survival was significantly increased (0% to 
50% and 67%). This protection was not seen in dogs which were infused with Z13752A and 
then given icatibant (Figure 12). Thus, at this time, there was a high number of VPBs (632 ± 
300, P<0.05 vs Z13752A alone) and all dogs exhibited a large number of episode of VT (22.5 
± 13.8, P<0.05 vs Z13752A alone). Furthermore, 58% of the Z13752A treated dogs 
fibrillated during the occlusion period in the presence of icatibant and no dog survived the 
combined occlusion-reperfusion insult. The severity of ventricular arrhythmias after icatibant 
alone was not significantly different from those seen in the controls (VPBs: 524 ± 166, VT 
episodes: 25 ± 10, VT: 73%, VF during occlusion: 46% and survival: 9%; not shown in the 
figure). 
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Figure 12. The effects of enalaprilate, Z13752A alone and with icatibant in comparison with 
controls on ventricular arrhythmias resulting from coronary artery occlusion and subsequent 
reperfusion. *P < 0.05 vs controls. 
3.3. Evaluation of the cardioprotective effects of preconditioning in combination with 
drug treatment 
This study aimed to explore whether elevation of bradykinin levels following 
administration of enalaprilate or Z13752A can provide additional protection to ischaemic 
preconditioning induced by a single 5 min occlusion of the LAD, 15 min and 60 min 
previously. 
3.3.1. Haemodynamic changes during coronary artery occlusion in preconditioned 
dogs in the presence of enalaprilate and Z13752A treatment 
These results are shown in Table 4. In all dogs, coronary artery occlusion resulted in 
significant decreases in arterial blood pressure, LVSP and coronary diastolic resistance. At the 
same time LVEDP and blood flow of the LCX coronary artery were increased. These changes 
were almost identical in all groups of dogs, except those preconditioned dogs with a 60 min 
reperfusion interval, in which Z13752A was given. In these dogs the increase in LVEDP 
following coronary artery occlusion was less marked than in the controls. Similarly, compared 
to the controls in preconditioned dogs, treated with either enalaprilate or Z13752A a 
significantly less marked reduction could be observed in positive and negative dP/dtmax during 
occlusion of the LAD (Table 4). 
Table 4. Haemodynamic changes during coronary artery occlusion in dogs subjected to preconditioning 15 and 60 min previously, either before 
or after the administration of enalaprilate andZ13752A. 
Control enalaprilate + PC 60 min R + Z13752A + PC 15 min R PC 60 min R + Z13752A 
(n = 16) PC 15 min R (n = 6) 
enalaprilate 
(n=13) (n = 6) (n = 12) 
Initial value max. change Initial value max. change Initial value max. change Initial value max. change Initial value max. change 
Arterial blood pressure 
systolic (mmHg) 125 ± 5 -14 ± 2 * 90 ± 5 -10 ± 3 * 87 ± 5 -8 ± 1* 100± 16 -12 ± 3* 100 ± 4 -10 ± 2 * 
diastolic (mmHg) 90 ± 4 -13 ± 1 * 53 ± 4 -8 ± 2 * 49 ± 4 -5 ± 2 * 62 ± 9 -8.5 ± 2* 62 ± 3 -8 ± 1* 
mean (mmHg) 102 ± 4 -13 ± 3 * 66± 4 -9 ± 2 * 61 ± 4 -6 ± 2 *U 75 ± 11 -9 ± 2* 74 ± 3 -9 ± 1* 
LVSP (mmHg) 128 ± 7 -16 ± 3 * 93 ± 4 -8 ± 3 * 85 ± 4 -10 ± 3 * 94 ± 10 -11± 3* 88 ± 3 -5 ± 0.8* 
LVEDP (mmHg) 6.0 ±0.3 12.7 ± 0.6* 4.3 ±0.4 11.2 ± 1.7* 3.3 ±0.3 14.5 ±0.4* 4.1 ± 1.0 10.1 ± 1.4* 4.1 ±0.2 8.5 ± 1.1*# 
LVdP/dW 
(+ve: mmHg s"') 2622 ±216 -644 ± 99* 1376 ± 262 -196 ± 81# 1450± 140 -250 ±101# 1505 ± 305 -143 ± 79U 2981 ±293 -247 ± 94# 
(-ve: mmHg s"1) 2914 ±242 -641 ±116* 1191 ± 189 -177 ± 40# 1169 ±227 -75 ± 31# 1906± 461 -302± 95# 2560 ± 182 -181± 88# 
Heart rate (beats min'1) 155 ± 4 1 ± 1 131 ± 6 5 ± 2 141 ±7.5 3 ± 1 133 ± 7 5 ± 2 124 ± 4 2 ± 1 
Coronary (LCX) diastolic 
blood flow (ml min'1) 
82 ± 8 14 ± 3 * 95 ± 9 19 ± 4 * 90 ± 6 23 ± 7 * 123 ± 15 15 ± 3* 97 ± 8 17 ± 4 * 
Coronary (LCX) diastolic 1.13 ± 0.12 -0.23 ± 0.05* 0.60 ± 0.09 -0.19 ±0.04* 0.58 ±0.08 -0.26 ± 0.09* 0.59 ± 0.07 -0.14 ± 0.03* -0.69 ± 0.07 -0.14 ±0.02* 
resistance (mmHg ml"1 min"1) 
*P < 0.05 vs initial (valuepre-occlusion); UP < 0.05 vs controls. 
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3.3.2. The effects of enalaprilate and Z13752A on the severity of myocardial ischaemia 
in preconditioned dogs 
The epicardial ST-segment elevation and the degree of inhomogeneity, following 
coronary artery occlusion, were markedly reduced in preconditioned dogs with 15 min 
reperfusion and also in dogs treated with enalaprilate (Figures 13a and b). These changes were 
abolished when the preconditioned dogs were treated with enalaprilate (Figures 13a and b). 
Figure 13. Changes in epicardial ST-segment elevation (a) and in the degree of 
inhomogeneity (b) during a 25 min occlusion of the LAD, in control dogs (open circles), in 
dogs given enalaprilate (open squares) and in preconditioned dogs with 15 min reperfusion, 
either in the absence (filled circles) or in the presence (filled squares) of enalaprilate. *P < 
0.05 vs controls. 
In dogs preconditioned 60 min prior to occlusion the epicardial ST-segment was slightly 
decreased whereas the degree of inhomogeneity was similar to that in the controls (Figure 14a 
and b). Enalaprilate, given to these preconditioned dogs did not modify ischaemia severity. 
Figure 14. Changes in epicardial ST-segment elevation (a) and in the degree of 
inhomogeneity (b) during a 25 min occlusion of the LAD in control dogs (open circles), in 
dogs given enalaprilate (open squares) and in preconditioned dogs with 60 min reperfusion, 
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either in the absence (filled circles) or in the presence (filled squares) of enalaprilate. *P < 
0.05 vs controls. 
Similarly, when Z13752A was infused in dogs preconditioned 15 mm pnor to 
prolonged occlusion, the marked protection, resulted either from preconditioning or Z13752A 
was completely abolished. Thus, changes in epicardial ST-segment (Figure 15a) and in the 
degree of inhomogeneity of electrical activation (Figure 15b) following coronary artery 
occlusion were as marked as in the controls. 
Figure 15. Changes in the epicardial ST-segment (a) and in the degree of inhomogenity of 
electrical activation (b) during a 25 min occlusion of the LAD in control dogs (open circles), 
in dogs treated with ZL3752A (open squares) and in preconditioned dogs with 15 min 
reperfusion, either in the absence (filled circles) or presence (open rhombs) of Z13752A. *P 
< 0.05 vs control. 
However, when Z13752A was given in dogs subjected to preconditioning 60 min prior 
to the 25 min occlusion of the LAD, the reduction in both the epicardial ST-segment (Figure 
16a) and the degree of inhomogeneity (Figures 16), resulted from Z13752A treatment was 
largely preserved. 
Figure 16. Changes in epicardial ST-segment (a) and in the degree of inhomogenity of 
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electrical activation (b) during a 25 min occlusion of the LAD in control dogs (open circles), 
in dogs treated with Z13752A (open squares) and in preconditioned dogs with 60 min 
reperfusion, either in the absence (filled circles) or presence (filled squares) of Z13752A. *P 
< 0.05 vs control. 
3.3.3. The effects of enalaprilate and Z13752A on the severity of ventricular 
arrhythmias in preconditioned dogs 
When enalaprilate was infused in dogs subjected to preconditioning either 15 min (Figure 
17) or 60 min (Figure 18) prior to occlusion of the LAD, no additional protection occurred 
against arrhythmias. There was even an attenuation in the antiarrhythmic protection, resulted 
either from drug treatment or preconditioning. For example, when enalaprilate was 
administered in dogs preconditioned 15 min prior to prolonged occlusion, the number of VPBs 
(204 ± 94), the number episodes of VT (2.0 ± 1.6) during occlusion were somewhat higher 
than either in dogs given enalaprilate alone or in dogs subjected to preconditioning 15 min 
prior to prolonged ischaemia without drug treatment (Figure 17). Although no dog fibnllated 
during the occlusion period, all the dogs died following reperfusion. Thus, similar to the 
controls, none of these preconditioned dogs treated with enalaprilate survived the combined 
ischaemia/reperfusion insult. 
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Figure 17. The severity of ventricular arrhythmias occurring during coronary artery 
occlusion and subsequent reperfusion in control dogs, in dogs treated with enalaprilate, in 
dogs preconditioned 15 min prior to prolonged occlusion either in the presence or the 
absence of enalaprilate. *P < 0.05 vs control. 
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When enalaprilate was given in preconditioned dogs with a 60 min reperfusion interval the 
severity of ventricular arrhythmias was again increased, compared to those dogs which were 
not preconditioned but treated with enalaprilate, and it was similar to those dogs which were 
subjected to preconditioning without drug treatment. Thus, the number of VPBs (252 ± 72), 
the number of episodes of VT (2.5 ± 1.2), the incidence of VT (54%) and the incidence of VF 
(38%) during occlusion were increased and survival reduced (0%) in these enalaprilate treated 
preconditioned dogs (Figure 18). 
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Figure 18. The severity of ventricular arrhythmias occurring during coronary artery 
occlusion and subsequent reperfusion in control dogs, in dogs treated with enalaprilate, and 
in dogs preconditioned 60 min prior to prolonged occlusion either in the presence or the 
absence of enalaprilate. *P < 0.05 vs control. 
In contrast, the antiarrhythmic effect of Z13752A was still present when it was given in 
preconditioned dogs either with 15 or 60 min reperfusion intervals. Thus, the number of VPBs 
(86 ± 28 and 56 ± 24), the number of episodes of VT (0.33 ± 0.33 and 0.33 ±0.18) and the 
incidences of both VT (14% and 25%) and VF (16% and 8%) during prolonged occlusion 
were significantly reduced. However, the protective effect of Z13752A against reperfusion 
induced ventricular arrhythmias was abolished in these preconditioned dogs. For example, if 
Z13752A was infused in dogs preconditioned 15 min (Figure 19) and 60 min previously 
(Figure 20), 67% and 59% of the dogs fibrillated during reperfusion and survival from the 
combined ischaemia-reperfusion insult again reduced to 17% and 33%. 
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Figure 19. The severity of ventricular arrhythmias occurring during coronary artery 
occlusion and subsequent reperfusion in control dogs, in dogs treated with Z13752A, and in 
dogs preconditioned 15 min prior to ischaemia either in the presence or the absence of 
Z13752A. *P < 0.05 vs control. 
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Figure 20. The severity of ventricular arrhythmias occurring during coronary artery 
occlusion and subsequent reperfusion in control dogs in dogs treated with Z13752A, and in 
dogs preconditioned 60 min previously either in the presence or the absence of Z13752A. *P 
< 0.05 vs control. 
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3.4. Evaluation of the cardioprotective effects of atrial natriuretic peptide during 
myocardial ischaemia and reperfusion in anaesthetised dogs 
3.4.1. The haemodynamic effects of atrial natriuretic peptide 
The maximum haemodynamic changes following ANP infusion, measured after the 
commencement of the infusion were reductions in arterial blood pressure (systolic 119 ± 7 to 
98 ± 7 mmHg; diastolic 77 ± 5 to 62 ± 5 mmHg, mean 91 ± 6 to 74 ± 6 mmHg, P < 0.05) and 
in positive and negative LVdP/dtm« (3417 ± 17 to 3155 ± 177 mmHg s"1 and 2875 ± 228 to 
2534 ± 217 mmHg s"1, respectively, P < 0.05). There were no significant changes in heart rate 
or in LVEDP. The most significant haemodynamic effect of ANP was a transient increase (of 
24 ± 5 ml min"1, from 110±10to l34±13ml min"1) in the left circumflex diastolic coronary 
blood flow and a decrease in the coronary resistance (of 0.27 ± 0.05 mmHg ml'1, from 0.78 ± 
0.11 to 0.51 ± 0.09 mmHg ml"1) measured 5 min after the onset of the ANP infusion.These 
changes, however, returned to the initial values prior to the commencement of the coronary 
artery occlusion. 
3.4.2. Haemodynamic changes resulting from coronary artery occlusion in control 
dogs and in dogs given atrial natriuretic peptide 
These results are summarised in Table 5. Occlusion of the LAD resulted in similar 
haemodynamic changes both in the controls and ANP treated dogs, except that the increase in 
LVEDP and the decrease in negative dP/dW following occlusion was significantly less marked 
in the ANP treated dogs (Table 5). 
Occlusion of the LAD resulted in an immediate and sustained increase in blood flow 
through the circumflex branch of the left coronary artery. This compensatory increase in blood 
flow was significantly higher in the ANP treated dogs than in the controls (Table 5). 
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Table 5. Haemodynamic changes following LAD coronary artery occlusion in dogs 
pretreated with either saline or atrial natriuretic peptide (ANP). 
Control (n 
initial value 
=14) 
max. change 
ANP (n= 
initial value 
= 11) 
max. change 
Arterial blood pressure 
systolic (mmHg) 118 ± 4 -14 ± 2.5* 104 ± 6 -9 ± 2* 
diastolic (mmHg) 84 ± 4 -12 ± 3 * 70 ± 5 -7 ± 2* 
mean (mmHg) 96 ± 4 -12 ± 3 * 81 ± 5 -8 ± 4* 
LVSP (mmHg) 123 ± 8 - 1 5 ± 4* 109 ± 4 -9 ± 2* 
LVEDP (mmHg) 5.5 ± 0.43 12.0± 0.79* 5.00 ±0 .00 9.00 ± 0.9*# 
L V d P / d W 
(+ve: mmHg s"1) 2359± 157 -589± 127* 3 2 2 1 ± 1 7 4 -512 ± 95* 
(-ve: mmHg s"1) 2655 ± 2 3 1 -630 ±135* 2592 ± 226 -278 ± 73 *# 
Heart rate (beats min"1) 154 ± 5 5 ± 1 137 ± 5 3 ± 1 
Coronary (LCX) diastolic 
blood flow (ml min"1) 
82 ± 8 14 ± 3* 104 ± 8 33 ± 6*# 
Coronary (LCX) diastolic 1.13 ± 0 . 1 2 -0.23 ± 0 . 1 2 
resistance (mmHg ml"1 min"1) 
*P< 0.05 vs initial value; # P< 0.05 vs control. 
0.72 ± 0.10 -0.23 ± 0.05* 
3.4.3. The effects of atrial natriuretic peptide on the severity of myocardial ischaemia 
The severity of myocardial ischaemia, assessed from changes in epicardial ST-segment 
elevation (Figure 21a) and the degree of inhomogeneity of electrical activation (Figure 21b) 
were significantly less marked in dogs given ANP than in the controls. 
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Figure 21. Changes in epicardial ST-segment (mV, a) and in the degree of inhomogeneity of 
electrical activation (ms, b) during a 25 min occlusion of the LAD coronary artery in control 
dogs (open circles) and in dogs given ANP (filled squares). *P < 0.05 vs controls. 
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3.4.4. The effects of atrial natriuretic peptide on ventricular arrhythmias following 
coronary artery occlusion and reperfusion 
The severity of ventricular arrhythmias resulting from coronary artery occlusion and 
reperfusion, in control and in ANP treated dogs is illustrated in Figure 22. In this study, there 
was a mean of 416 ± 87 VPBs in the control dogs during coronary artery occlusion, and all the 
dogs exhibited VT at some stages during the period of ischaemia with a mean of 12.1 ± 4.2 
episodes of VT per dogs. Eight of the 14 dogs (57%) fibrillated during the occlusion period 
and the remaining six dogs (43%) died following reperfusion. Thus, no control dog survived 
the combined ischaemia-reperfusion insult. 
These ischaemia and reperfusion induced arrhythmias were much less pronounced in dogs 
given ANP (Figure 22). There was a mean of only 26 ± 12 VPBs and 6 out of 11 dogs had VT 
with a mean of 0.7 ± 0.03 VT episodes and only two dogs (18%) treated with ANP fibrillated 
during reperfusion. Thus, 64% of the ANP-treated dogs survived the combined ischaemia-
reperfusion insult (Figure 22). 
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Figure 22. Severity of ventricular arrhythmias during a 25 min occlusion of the LAD and the 
overall survival following the combined occlusion-reperfusion insult in control and in ANP 
treated dogs. *P < 0.05 vs control. 
3 6 
4. DISCUSSION 
4.1. Cardioprotection induced by a single brief period of coronary artery occlusion 
In this part of study we examined whether one brief (5 min) period of preconditioning 
occlusion can protect the myocardium against those life-threatening ventricular arrhythmias 
that occur during a subsequent more prolonged ischaemic insults and, whether the duration of 
this protection is similar to that seen when preconditioning is induced by two periods of 
coronary artery occlusion of the same duration. 
The results of the present study demonstrate that in anaesthetised dogs a single 5 min 
period of coronary artery occlusion provides protection against the ischaemia and reperfusion-
induced ventricular arrhythmias and, that this protection is as marked as with two periods of 
preconditioning occlusion (6). The protection is most marked if the time interval between the 
preconditioning occlusion and the prolonged ischaemia is 5 min. After this time the 
antiarrhythmic effect starts to fade and 60 min after the preconditioning stimulus the protection 
is almost completly lost. Thus, the duration of this antiarrhythmic protection is almost identical 
with that of seen when preconditioning is induced by two 5 min occlusion; i.e. the 
antiarrhythmic protection last less than 60 min (6). 
It is well established that short periods (3-5 min) of coronary artery occlusion in 
experimental animals (rats, dogs, pigs) and also in humans reduce the severity of ventricular 
arrhythmias that occur when the same artery is occluded for a longer period (6,43,99). For 
example, in dogs Vegh and colleagues reported that one or two short periods of 
preconditioning occlusion significantly reduce the number of ectopic beats and the incidences 
of ventricular tachycardia and ventricular fibrillation resulting from a subsequent prolonged 
ischaemia and increase survival after the reperfusion of the ischaemic myocardium (6). They 
have also demonstrated that the optimum period for the preconditioning occlusion is 3 min in 
rats and 5 min in dogs (6). They have also pointed out that the protection against arrhythmias 
is largely lost 60 min after the commencement of preconditioning (6). In rabbits, Miura and 
colleagues (40) showed that a single episode of preconditioning occlusion for 2 min results in 
only a slight protection. However, when this occlusion was repeated twice, the reduction in 
infarct size was as the same as with preconditioning for 5 min. These findings suggest that the 
cardioprotective effect of preconditioning can be enhanced by increasing the number of the 
occlusion if their duration is 2 or 3 min but it is likely that a single 5 min period of ischaemia 
can almost result in maximal protection at least in rabbits and in dogs. In contrast, Lawson and 
colleagues showed in rat isolated blood perfused hearts that an increase in the number of 
preconditioning cycles (5 min of each) results in a "dose-dependent" reduction in the number 
of ventricular premature beats and in the incidences of ventricular tachycardia and ventricular 
fibrillation (36). These results might indicate species-dependent and end-point-dependent 
differences in the generation of cardioprotection associated with ischaemic preconditioning. 
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In summary, the present studies demonstrate that in anaesthetised dogs one brief (5 min) 
period of preconditioning occlusion results in marked protection against ventricular 
arrhythmias resulting from a subsequent, more prolonged period of ischaemia. Although this 
protection is marked it fades within 60 min. The time course of this antiarrhythmic protection 
is similar to that seen with two 5 min periods of occlusion (6) in the canine. 
4.2. The cardioprotective effects of enalaprilate and Z13752A 
The aim of this part of the study was to explore whether elevation of bradykinin levels by 
other means than ischaemic preconditioning, such as the inhibition of bradykinin breakdown, 
may result in protection against arrhythmias in our canine model of ischaemia/reperfusion. For 
this purpose, we have used the ACE inhibitor, enalaprilate and also the combined ACE/NEP 
inhibitor Z13752, since both drugs can elevate bradykinin levels. 
Our result showed that both enalaprilate and Z13752A, given intravenously in 
anaesthetised dogs prior to an ischaemic insult resulted in significant haemodynamic changes 
(e.g. reduction in arterial blood pressure, LVSP, negative LVdP/dtmax and coronary vascular 
resistance as well as increase in coronary blood flow). Furthermore, in these treated dogs there 
was a less marked increase in LVEDP during coronary artery occlusion. Both enalaprilate and 
Z13752A significantly reduced the severity of myocardial ischaemia, as assessed by changes in 
epicardial ST-segment elevation and in the degree of inhomogeneity of electrical activation, as 
well as by evaluating the severity of ventricular arrhythmias that resulted from a 25 min 
occlusion and then reperfusion of the left anterior descending coronary artery. For example, 
compared to the control group in which no dog survived the combined ischaemia-reperfiision 
insult, 50% of the dogs treated with enalaprilate and 67% of the animals given Z13752A 
survived. This degree of protection against arrhythmias is similar to that described previously, 
in this model, with ischaemic preconditioning (5), by cardiac pacing (24) and following the 
local intracoronary infusion of bradykinin (60). 
The cardioprotective effects of ACE inhibitors are well demonstrated in both experimental 
animals (67,68) and in humans (69,70). The evidence that ACE inhibitors reduce the incidence 
and the severity of ventricular arrhythmias comes first from studies, performed in rat isolated 
perfused hearts (100,101). Clinical studies (102) also supports these findings, showing that in 
heart failure patients the severity of arrhythmias is less pronounced if they are treated with 
captopril or enalaprilate than in patient without ACE inhibitor therapy. The evidence that the 
cardioprotective effects of ACE inhibitors, at least in part, are mediated by bradykinin derived 
from those studies in which the protective effects of ACE inhibitors could be abolished by the 
bradykinin B2 receptor antagonists icatibant (HOE-140) (64). This resulted in an assumption 
that the most likely explanation, for the cardioprotective effects of ACE inhibitors, is their 
ability to prevent the breakdown of bradykinin (103). The Groningen group of van Glist and 
de Langen (104-107) have extensively investigated the protective effects of various ACE 
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inhibitors in a pig model of ischaemia and reperfusion. They have showed that long term 
therapy with ACE inhibitors increased survival from the combined ischaemia and reperfusion 
insult (104,105) and it was more difficult to induce ventricular arrhythmias in the presence of 
an ACE inhibitor (106,107). These authors also concluded that the antiarrhythmic effect of 
ACE inhibitors are mediated through the elevation of bradykinin. 
There has been just one study, in Lewis inbred rats, that has examined the effects of an 
inhibitor of neutral endopeptidase 24.11 on myocardial reperfusion injury (76). Using the Ciba-
Geigy inhibitor CGS 24592 Yang and colleagues (76) showed a reduction in infarct size and 
this was similar to that resulted from ramiprilat administration. The protection was abolished by 
icatibant but unaffected by the ANF receptor antagonist HS-142-1. Their conclusion was that 
the infarct size reduction, following NEP inhibition, was mediated by kinins. Although the 
primary endpoint of these authors was to examine the effect of NEP inhibitor of the infarct 
size, the fact that the ventricular premature complexes which did arise following reperfusion 
were reduced, albeit not significantly, by this NEP inhibitor is again suggestive of a role for 
kinins in cardioprotection. 
The cardioprotective effect of elevated levels of bradykinin resulting from inhibition of 
cardiac NEP activity has been recently demonstrated in isolated human cardiac membranes 
(74). In these preparations, in which there is a low enzymatic activity of ACE, bradykinin 
metabolism is mediated mostly by NEP. These results suggest that inhibition of cardiac NEP 
activity could be cardioprotective by elevating the local concentration of bradykinin in the 
heart. 
In the present experiments the most likely explanation for the protective effects of 
Z13752A is potentiation of the cardioprotective effects of bradykinin by inhibition of its 
breakdown. Although ACE inhibition presumably plays a role, since Z13752A inhibits both 
enzymes, the evidence from the IC50 values {0.0032 pM against ACE; 0.0018 pM against 
NEP; (78,79)} and from the present experiments showing a more marked potentiation of 
bradykinin vasodilator than of inhibition of angiotensin vasopressor responses in the presence 
of Z13752A (Figure 9 and 10), suggests a predominant effect on neutral endopeptidase 24.11. 
Indeed, responses to angiotensin II itself were potentiated by the drug (Figure 9), as in the 
human studies of Richards et al. (108), an effect attributed by them to reduced angiotensin II 
clearance. The fact that the protection against arrhythmias was completely abolished by 
icatibant, a selective antagonist of bradykinin at B2 receptors, and that this drug also abrogated 
the changes in ST-segment elevation and in the degree of inhomogeneity of electrical 
activation within the ischaemic area, both indices of ischaemia severity, again supports the view 
that the cardioprotection observed is largely kinin-mediated. We do not know if this protection, 
like that afforded by bradykinin itself (62), is ultimately due to nitric oxide (NO) and 
prostacyclin generated and released as a result of an effect of bradykinin on endothelial B2 
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receptors. However, it is known that NEP inhibition leads to an increase in NO production in 
canine isolated coronary micro vessels, and that this is mediated by kinins (109). 
Besides kinin breakdown, NEP is also concerned with the breakdown of other peptides 
(67) such as endothelin and ANP. Z13752A when infused intravenously to dogs led to 
significant elevation of ANP levels (Morazzoni et al. unpuplished) and in our experiment ANP 
when infused intravenously in the model we have used in the present study also reduces 
ischaemia and arrhythmia severity during occlusion and reperfusion and could conceivably play 
a role in the cardioprotective effects of Z13752A Aso there is evidence that bradykinin can 
upregulate ANP receptors (110), therefore elevation of bradykinin levels may potentiat the 
cardioprotective effects of ANP. 
Athough selective ANP receptor antagonists are available we have no means of 
examining such a role for ANP in this particular large animal model. The finding that icatibant 
abolishes the cardioprotection resulting from Z13752A administration however would argue 
against this possibility. 
In summary, enalaprilate a pure ACE inhibitor, and Z13752A a combined ACE/NEP 
inhibitor protect the heart against the severe consequences of ischaemia and evidence is 
adduced to suggest that this protection is mediated by bradykinin. 
We believe that these results add weight to the hypothesis (111) that bradykinin acts as an 
endogenous myocardial protective substance (36) and that it plays a role in the protection 
afforded by ischaemic preconditioning. This hypothesis, the evidence for which has been 
recently reviewed (112), suggests that brief (preconditioning) periods of ischaemia result, like 
clinical coronary angioplasty, in the enhanced release of bradykinin from the heart. This then 
acts on endothelial B2 receptors and stimulates the generation and release of other mediators 
(Figure 1), which, like bradykinin itself, are able to protect the heart against the consequences 
of prolonged ischaemia. That NO is a particularly important mediator is borne out by the 
marked attenuation of the cardioprotective effects of bradykinin, given by intracoronary 
administration, by inhibitors of the L-arginine-NO pathway (62). 
4.3. The effect of pharmacological and mechanical preconditioning on arrhythmias; 
the role of bradykinin 
This part of the study aimed to examine whether the protection against arrhythmias, 
resulting from preconditioning can be increased by an additional pharmacological stimulus. We 
started from the assumption that, if bradykinin is involved in the antiarrhythmic effect of 
ischaemic preconditioning, then enhancement of bradykinin levels by the administration of the 
ACE inhibitor enalaprilate or the combined ACE/NEP inhibitor Z13752A would increase the 
protection resulting from preconditioning. 
In our experiments both enalaprilate and Z13752A (Figure 12) as well as preconditioning 
with a single, brief period (5 min) coronary, artery occlusion (Figure 8) results in protection 
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against ventricular arrhythmias that occur during a subsequent prolonged ischaemia and 
reperfiision. However, these stimuli applied together, failed to enhance or prolong the 
protection resulting from either ischaemic preconditioning or drug treatment alone (Figures 17-
20). Thus, both enalaprilate and Z13752A, which are alone protective, were unable to provide 
additional protection in preconditioned dogs. Indeed, the protective effects of these drugs 
(particularly of enalaprilate which is less potent than Z13752A), against ischaemia and 
reperfusion-induced ventricular arrhythmias, were markedly attenuated in preconditioned dogs. 
Ribuot and colleagues (113) showed in anaesthetized dogs that 1 ng kg'1 min'1 dose of 
bradykinin, given in intracoronary infusion, 15 min before and throughout the 60 min 
occlusion of the LAD significantly reduced the amount of noradrenaline released following 
reperfiision of the ischaemic myocardium. This was accompanied by a significant reduction in 
the incidence of reperfusion-induced sustained VT. They concluded that the protective effects 
of bradykinin against reperfusion-induced arrhythmias could be associated with a reduction in 
cardiac noradrenaline release. Similarly, Vegh and colleagues (60) showed in anaesthetised 
dogs, that the intracoronary infusion of bradykinin in a dose of 25 ng kg'1 min'1, given 10 min 
before and throughout the entire occlusion period results in significant reduction in the severity 
of myocardial ischaemia (reduced ST-segment elevation and degree of inhomogeneity of 
electrical activation) and supresses ventricular arrhythmias. This reduction in ischaemia and 
arrhythmia severity following bradykinin was similar to that seen with ischaemic 
preconditioning. This group has also demonstrated that the protective effect of ischaemic 
preconditioning against ventricular arrhythmias is abolished by icatibant, indicating the 
involvement of bradykinin and the subsequent activation of bradykinin B2 receptors as the 
consequence of preconditioning (61). Recently, Leesar and colleagues (114) showed that in 
patients undergoing coronary angioplasty the intracoronary infusion of 2.5 pg min'1 dose of 
bradykinin for 10 min induced similar protection than preconditioning. Furthermore, in control 
patient, the ST-segment shift, on the intracoronary and surface electrocardiogram, was 
significantly greater during the first balloon inflation than that during the second or the third 
inflation; consistent with ischaemic preconditioning. However, in bradykinin-treated patients, 
ST-segment shift during the first balloon occlusion was significantly smaller than in the control 
group, and there were no appreciable differences in ST-segment shifts during the three 
inflation. They concluded that bradykinin preconditions the human myocardium against 
ischaemia "in vivo". 
There is also some evidence that ACE inhibitors can potentiate the effect of a subthreshold 
preconditioning stimulus "in vitro" and "in vivo". For example Morris and colleagues (115) 
showed that in human trabeculae a subthreshold preconditioning stimulus and the ACE 
inhibition alone did not enhance the recovery from a 90 min period of stimulated ischaemia. 
However, when these two stimuli were combined a marked protection was observed and this 
could be blocked by icatibant. Similarly, Miki and colleagues (116) reported that neither the 
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subthreshold preconditioning stimulus nor captopril treatment alone limits myocardial infarct 
size in rabbits subjected to a 30 min period of coronary occlusion and subsequent 3 h 
reperfusion. However, combination of these two stimuli potentiated the infarct size limiting 
effect and that this protection was also abolished by icatibant. 
In our experiments in dogs which were subjected either to a single 5 min preconditioning 
occlusion (if the reperfiision period was less than 60 min) or to drug treatment we have found 
a significant reduction in the severity of arrhythmias, resulted from a 25 min occlusion of the 
LAD and that survival from the combined occlusion reperfusion insult was markedly increased. 
However, combination of these two stimuli failed to give further protection, the antiarrhythmic 
effects resulted from drug treatment was even attenuated in the presence of preconditioning. 
We do not know why the protection resulted from enalaprilate and Z13752A administration, 
especially against reperfusion-induced ventricular arrhythmias, disappeares in the presence of 
preconditioning in this canine model. There is some evidence that high levels of bradykinin can 
facilitate, rather than alleviate reperfusion arrhythmias in guinea pigs and in human myocardial 
ischaemia models (117). According to this study, bradykinin released during myocardial 
ischaemia accumulates in the sympathetic nerve endings and this may facilitate exocytotic and 
carrier mediated noradrenaline release. This enhanced noradrenaline release than contributes to 
coronary vasoconstriction and to the generation of ventricular arrhythmias following 
reperfusion. This unfavourable effect of bradykinin was abolished by the bradykinin B2 
receptor antagonist, icatibant (117). However, icatibant was not able to inhibit noradrenaline 
release unless enalaprilate or a combined kininase I and kininase II inhibitor was present, 
indicating that under these conditions endogenous bradykinin levels at the nerve ending may 
not be high enough to facilitate ischaemic noradrenaline release. Furtheremore, Chulak and 
colleagues (118) recently showed the modulatory effect of bradykinin on electrically-induced 
noradrenaline release in isolated atria from normal and B2 knockout transgenic mice 
preincubated with noradrenaline. They showed that the lower concentrations of bradykinin 1, 3 
and 10 nM did not significantly alter the outflow of noradrenaline whereas the higher 
concentrations of bradykinin 30 and 100 nM enhanced the release of noradrenaline. This 
facilitatory effect of bradykinin was inhibited by icatibant but unaffected by the bradykinin Bi 
receptor antagonist. In the presence of enalaprilate or mergepta (kininase I), already the lower 
dose of bradykinin (10 nM) significantly increased the stimulation-induced outflow of 
noradrenaline. They concluded that the facilitatory effect of bradykinin on noradrenaline 
release in the mouse atria is mediated by presynaptic bradykinin B2 receptor which is linked to 
protein kinase C. Similarly, Silva and colleagues (119) showed that bradykinin concentration-
dependently facilitated the release of noradrenaline evoked by electrical stimulation from the 
rat ventricle wall and that this was further enhanced in the presence of captopril. They have 
also shown that the bradykinin facilitated noadrenaline release and its enhancement by 
captopril was abolished by icatibant and also by the removal of the endocardium. They 
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concluded from these results that bradykinin is able to facilitate noradrenaline release from the 
sympathetic nerve endings through the activation of B2 receptors, located in endocardial cells. 
Although we do not know whether a similar mechanism could explain that the antiarrhythmic 
protection, resulted from preconditioning and enalaprilate or Z13752A treatment, is markedly 
attenuated if these two stimuli are applied together, but it seems very likely that under these 
conditions an enhanced noradrenaline release may occur and this might contribute to the 
generation of ventricular arrhythmias. The validation of this hypothesis, in our canine model, 
requires further investigation. 
4.4. New findings 
1. We have showed that one brief (5 min) period of preconditioning occlusion can protect the 
myocardium against those life-threatening ventricular arrhythmias that occur during a 
subsequent more prolonged ischaemia-reperfusion insult. The most marked protection 
occurs 5 min after preconditioning and then the antiarrhythmic effect starts to fade. Thus, 
the duration of this antiarrhythmic effects is similar to that seen when preconditioning is 
induced by two 5 min occlusion; i.e. the antiarrhythmic protection lasts less than 60 min. 
2. We have demonstrated that the ACE inhibitor enalaprilate and the combined ACE/NEP 
inhibitor Z13752A, both administrated intravenously 60 min prior to coronary artery 
occlusion, suppress the various types of ischaemia-induced ventricular arrhythmias and 
reduce the incidence of VF following reperfusion in anesthetised dogs. 
3. However, if these drugs are given to preconditioned dogs the antiarrhythmic protection, 
resulted either from ischaemic preconditioning or drug treatment, is largely lost. 
4. We have described for the first time a protective effect of ANP against ischaemia and 
reperfusion-induced ventricular arrhythmias in dogs. 
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